Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001111 | 0.83 | TGFBR1 (0.44) | KDM4EPKMGPR119TGFBR1MET | |
| SCHEMBL31001109 | 0.83 | TGFBR1 (0.44) | KDM4EPKMGPR119TGFBR1MET | |
| SCHEMBL23442868 | 0.82 | HCAR1 (0.47) | GPR119MET | |
| SCHEMBL31637159 | 0.81 | TGFBR1 (0.44) | KDM4EPKMGPR119TGFBR1FAAH | |
| SCHEMBL17394745 | 0.79 | GPR119 (0.46) | KDM4EPKMGPR119TGFBR1FAAH | |
| SCHEMBL17394748 | 0.79 | BACE1 (0.43) | KDM4EPKMGPR119TGFBR1FAAH | |
| SCHEMBL17394747 | 0.78 | BACE1 (0.47) | KDM4EPKMGPR119TGFBR1BACE1 | |
| SCHEMBL19461156 | 0.78 | FNTA (0.46) | KDM4EPKMGPR119TGFBR1FAAH | |
| SCHEMBL30963004 | 0.76 | CHEK1 (0.46) | TGFBR1 | |
| SCHEMBL31001071 | 0.75 | NR3C1 (0.55) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-04-25 | — | — | US | disclosed |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2023-01-19 | — | — | US | disclosed |
| WO-2021104461-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | 南京明德新药研发有限公司 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | CHEK1, CHEK2, DDB1 | KDM4E 1878/4885PKM 992/4885GPR119 2271/4885 |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | CHEK1, CHEK2, DDB1 | KDM4E 1878/4885PKM 992/4885GPR119 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.